Medical Device Procurement in France: A Supplier's Guide [2026]

France is the second-largest medical device market in Europe, with annual healthcare spending exceeding EUR 300 billion and a strong public hospital network. The French procurement system is highly structured, with central purchasing bodies, strict regulatory oversight from ANSM, and a reimbursement framework that directly shapes device adoption. Understanding these mechanisms is essential for suppliers aiming to enter or expand in the French market.

Regulatory authority and approval pathway

France operates under the EU Medical Device Regulation (MDR 2017/745). The Agence nationale de securite du medicament et des produits de sante (ANSM) is the competent authority responsible for market surveillance, vigilance, and enforcement.

• CE marking: Mandatory for all medical devices placed on the French market, obtained through an EU-recognized Notified Body.
• ANSM registration: Manufacturers and authorized representatives must register with ANSM and declare their devices before market placement.
• HAS evaluation: The Haute Autorite de Sante evaluates clinical benefit (Service Attendu — SA) and improvement in clinical benefit (Amelioration du Service Attendu — ASA) for devices seeking reimbursement. A favorable HAS opinion is critical for hospital adoption.
• LPPR listing: Devices must be listed on the Liste des Produits et Prestations Remboursables (LPPR) to qualify for reimbursement by the national health insurance (Assurance Maladie).

Without LPPR listing, hospitals face financial disincentives to purchase your device. Start the EU MDR compliance and HAS evaluation processes in parallel to avoid unnecessary delays.

Key procurement platforms and channels

French public hospital procurement follows the Code de la commande publique (public procurement code):

• UGAP (Union des Groupements d'Achats Publics): France's national central purchasing body. UGAP framework agreements allow hospitals to purchase without running their own tenders. Winning a UGAP reference is a major commercial accelerator.
• UniHA and Resah: Hospital purchasing groups that aggregate demand across public hospitals. UniHA covers university hospitals; Resah covers smaller establishments.
• BOAMP and JOUE/TED: Public tenders are published on the Bulletin Officiel des Annonces des Marches Publics (BOAMP) and, above EU thresholds, on TED.
• Individual hospital tenders: Centres Hospitaliers Universitaires (CHUs) and Centres Hospitaliers (CHs) run their own procurement for non-framework purchases.

Monitoring BOAMP, TED, UGAP, and individual hospital portals simultaneously requires automation. MedStrato's tender intelligence platform tracks French procurement opportunities across all channels.

Compliance requirements for tenders

• Language: All submissions must be in French. Technical documentation, IFU, and labeling must be translated.
• DC1/DC2 forms: Administrative declarations (formerly DC1 and DC2) are required for all public tender responses, covering company identity, financial standing, and tax compliance.
• ISO 13485: Quality management system certification is expected.
• Clinical evidence: French evaluators place significant weight on clinical data. HAS-evaluated devices with ASA ratings of I-III have strong procurement advantages.
• Environmental criteria: Increasingly, French tenders include sustainability criteria aligned with the Plan National Sante Environnement.

Market size and opportunity

France's medical device market is valued at approximately EUR 32 billion. The country has over 3,000 public and private healthcare establishments. Key growth areas include:

• Home healthcare devices: France is investing heavily in shifting care to home settings (virage ambulatoire), creating demand for connected monitoring devices.
• Digital therapeutics: The PECAN program (Prise en Charge Anticipee Numerique) provides early access pathways for digital health devices.
• Surgical innovation: French CHUs are active adopters of surgical robotics and minimally invasive technologies.

Tips for foreign suppliers

1. Prioritize HAS evaluation: Without a HAS opinion and LPPR listing, hospital procurement teams will deprioritize your product regardless of clinical merit.
2. Engage UGAP and UniHA: Framework agreements with central purchasing bodies provide the highest-volume commercial pathway.
3. Build KOL relationships: French clinical opinion leaders significantly influence hospital purchasing committees. KOL mapping tools can accelerate this process.
4. Appoint a local distributor: A French-speaking commercial partner with existing hospital relationships dramatically shortens the sales cycle.
5. Automate tender responses: French tenders have strict format and deadline requirements. Tender automation ensures compliance and speed. Book a demo to learn more.